Evolus

Evolus

Pharmaceuticals
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

$519.2M

Market Cap • 9/18/2026

2012

(14 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

P/S

1,6

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

EPS

Market Cap

Market Cap

519,2M

EV

638,8M

EV/Revenue

2

EV/EBITDA

-65,3

EV/EBIT

-34,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-679,8M

Profitability

Gross Margin

66,7%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

3,1%

Capex/Revenue

0,9%

Capex/D&A

32,6%

Capex/OCF

-18,8%

SBC/OCF

% PPE

4,6%

% Goodwill

8,6%

ROE

138,6%

ROIC

Growth

CAGR Revenue 5Y

32,8%

CAGR Op. Income 5Y

-31,5%

CAGR Net Income 5Y

-23,5%

CAGR EPS 5Y

-32,7%

CAGR OCF 5Y

13,4%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

1,7

Quick Ratio

1,1

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium